The aim of this Research Training Program is to recruit and prepare highly qualified physician/scientists for an academic research career in medical or gynecological oncology by developing research skills in cancer biology and therapy. The general areas of training include: 1) Clinical Hematopoietic Cell Transplantation;2) Immunology and Vaccine Development;3) Transplantation Biology;4) Stem/Progenitor Cell Biology;5) Women's Cancer Research;6) Genito-urinary Cancer Research;7) Gastro-intestinal Cancer Research;8) Human Biology. All trainees will be members of the Hematology/Oncology or Gynecologic Oncology Fellowship Programs of the University of Washington/Fred Hutchinson Cancer Research Center. Trainees receive specific didactic training in the fundamentals of oncology research, including biostatistics, protocol development, data analysis, medical and research ethics, use and care of animals in research and use of human subjects in research. The majority of the trainee's time is spent conducting research under the direct supervision of a faculty mentor selected by the trainee with additional guidance from the Fellowship Training Program Committee.

Public Health Relevance

In 2009, approximately 1.48 million individuals in the United States will be diagnosed with cancer and 563,000 will die of the disease. Clearly, new approaches to cancer prevention, diagnosis and treatment are needed, and these will only come from new insights achieved through research. This Research Training Program is designed to directly respond to this need by recruiting and training exceptionally qualified physician scientists for a career in cancer research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Institutional National Research Service Award (T32)
Project #
5T32CA009515-30
Application #
8690777
Study Section
Subcommittee B - Comprehensiveness (NCI)
Program Officer
Lim, Susan E
Project Start
1985-07-01
Project End
2015-06-30
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
30
Fiscal Year
2014
Total Cost
Indirect Cost
Name
University of Washington
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
City
Seattle
State
WA
Country
United States
Zip Code
98195
Chow, Victor A; Shadman, Mazyar; Gopal, Ajay K (2018) Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma. Blood 132:777-781
Salk, Jesse J; Schmitt, Michael W; Loeb, Lawrence A (2018) Enhancing the accuracy of next-generation sequencing for detecting rare and subclonal mutations. Nat Rev Genet 19:269-285
Veatch, Joshua R; Lee, Sylvia M; Fitzgibbon, Matthew et al. (2018) Tumor-infiltrating BRAFV600E-specific CD4+ T cells correlated with complete clinical response in melanoma. J Clin Invest 128:1563-1568
Greenbaum, Adam M; Green, Damian J; Holmberg, Leona A et al. (2018) Bendamustine, etoposide, and dexamethasone to mobilize peripheral blood hematopoietic stem cells for autologous transplantation in non-Hodgkin lymphoma. Blood Res 53:223-226
Disis, Mary L; Stanton, Sasha E (2018) Immunotherapy in breast cancer: An introduction. Breast 37:196-199
Paulson, K G; Voillet, V; McAfee, M S et al. (2018) Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA. Nat Commun 9:3868
Baker, Kathryn T; Salk, Jesse J; Brentnall, Teresa A et al. (2018) Precancer in ulcerative colitis: the role of the field effect and its clinical implications. Carcinogenesis 39:11-20
Graham, Laura; Banda, Kalyan; Torres, Alba et al. (2018) A phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration resistant prostate cancer. Invest New Drugs 36:458-467
Dossa, Robson G; Cunningham, Tanya; Sommermeyer, Daniel et al. (2018) Development of T-cell immunotherapy for hematopoietic stem cell transplantation recipients at risk of leukemia relapse. Blood 131:108-120
Vandeven, Natalie; Lewis, Christopher W; Makarov, Vladimir et al. (2018) Merkel Cell Carcinoma Patients Presenting Without a Primary Lesion Have Elevated Markers of Immunity, Higher Tumor Mutation Burden, and Improved Survival. Clin Cancer Res 24:963-971

Showing the most recent 10 out of 243 publications